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Abstract 
Extracellular vesicles, exosomes and microvesicles, play a fundamental role in the activity of the 
nervous system, participating in signal transmission between neurons and providing the interaction 
of central nervous system (CNS) with all body systems. In various pathological processes in CNS 
extracellular vesicles can help eliminate toxic agents from cells, but at the same time they provide 
the distribution of these agents into healthy cells. Thus, extracellular vesicle cargo varies on the 
functional state of the CNS, the analysis of EV molecular content contributes to the development of 
non-invasive methods for the diagnosis of many CNS diseases. Extracellular vesicles of neuronal 
origin can be isolated from various biological fluids due to their ability to cross the blood-brain 
barrier (BBB). Today, the diagnostic potential of almost all toxic proteins involved in nervous 
system disease pathogenesis, specifically α-synuclein, tau protein, SOD1, FUS, LRRK2 as well as 
some synaptic proteins, has been proven. Special attention is paid to extracellular RNAs mostly 
associated with EVs, which are important in the onset and development of many neurodegenerative 
diseases. Depending on parental cell type, extracellular vesicles may have different therapeutic 
properties, including neuroprotective, regenerative, anti-inflammatory, etc. Also, modern 
modification approaches allow loading EVs with specific molecules and changing their surface 
molecules to achieve targeting of various cells, including neurons. Due to nano size, biosafety, 
ability to cross the BBB, possibility of targeted delivery and the lack of an immune response, 
extracellular vesicles are a promising vehicle for the delivery of therapeutic substances for the 
treatment of neurodegenerative diseases and drug delivery to the brain. This review describes 
modern approaches of diagnosis and treatment of CNS diseases using extracellular vesicles. 
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Extracellular vesicles (EVs) are membrane particles of cellular origin involved in the regulation of 
many physiological and pathological processes in the body (Chulpanova et al., 2018a; Hessvik and 
Llorente, 2018; Galieva et al., 2019). EVs are produced by almost all the cells of body and provide 
intercellular communication, transport of signal and other biologically active molecules toward 
target cells. (Hartmann and Burg, 1989; Merchant et al., 2017). EVs play an important role in the 
functioning of nervous system, providing not only the communication of nerve cells between 
themselves and glial cells, but also the interconnection of the central nervous system (CNS) with all 
body systems (Chivet et al., 2012). In CNS pathologies EVs play a dual role. On the one hand, they 
help maintain cellular homeostasis, cleaning the nervous system of protein aggregates and other 
pathogenic agents, however, they can also transfer toxic substances to healthy cells, mediating their 
spread throughout the body and burdening diseases. Pathogenic role of EVs is shown in 
neurodegeneration, neuroinflammation, cancers and disorders that affect CNS, for example, 
lysosomal storage disorders (Caruso Bavisotto et al., 2019). 
In various pathological processes, EVs undergo significant changes in composition, quantity and 
size. Knowledge of these changes makes it possible to identify new biomarkers of various diseases 
for sensitive and specific diagnosis (Wong and Chen, 2019). Today, special attention is paid to the 
diagnostic potential of pathogenic proteins, synaptic proteins, and extracellular RNAs inside EVs. 
EVs largely replicate cell therapy success. It is common to find works that investigate the 
therapeutic potential of native exosomes isolated from dendritic cells (Pitt et al., 2016; Sousa et al., 
2017), macrophages (Choo et al., 2018), hematopoietic stem cells (Radosinska and Bartekova, 
2017), endothelial cells (Xiao et al., 2017) and mesenchymal stem cells (MSCs) (Lopez-Verrilli et 
al., 2016; Mathew et al., 2019). MSC-derived exosomes contain cytokines, trophic growth factors, 
signal lipids, mRNAs and regulatory miRNAs, which makes them an attractive therapeutic agent 
for use in cell-free regenerative medicine (Phinney and Pittenger, 2017). 
When developing new strategies for CNS disease treatment, special attention is paid to EVs due to 
their ability to cross the blood-brain barrier (BBB) (Matsumoto et al., 2017a). The mechanisms for 
EV passing through the BBB remain controversial and require further investigation. Malignant 
neoplasms, inflammatory processes and other pathological conditions of CNS can lead to 
dysfunction of the BBB and the substance flow of through it, which is partly due tight junction 
disruption (Garcia-Romero et al., 2017). It is assumed that normal transport through the BBB can 
occur through vesicular transcytosis, which is divided into receptor-mediated transcytosis (RMT) 
and adsorptive-mediated transcytosis (AMT). RMT process occurs via a binding with specific 
cellular receptors, but AMT is mediated by adsorption of cationic particles to the anionic 
components of the plasma membrane. In case of AMT there is less affinity and higher throughput. It 
is shown that EVs can cross the BBB through the mechanism of adsorptive-mediated transcytosis 
(Matsumoto et al., 2017b). Although RMT is more commonly used for therapeutic drug deliver to 
the brain due to the modification of surface ligands (Preston et al., 2014). 
There are various methods of EV modification that allow it to be used as vehicle for therapeutic 
agent delivery to target cells. Drug targeted delivery is achieved by modifying of EV surface 
molecules. To ensure nerve cell targeting, rabies virus glycoprotein is most often used whereas it 
binds to an acetylcholine receptor of nerve cells (Alvarez-Erviti et al., 2011; Huey et al., 2017; 
Phoolcharoen et al., 2017). 
1 Cells of Nervous System – potential source and targets of EVs  
Nervous tissue is composed of neurons and neuroglia. Neurons are highly polarized cells, most of 
them consist of a body and two functionally and morphologically different processes: dendrites and 
axon (Giordano-Santini et al., 2016), that provide information flow through the nervous system 
(Takano et al., 2015). Neuroglia are involved in the metabolism and maintenance of brain 
homeostasis, neuron survival, development and modulation of synaptic transmission, distribution of 
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nerve impulses, determination of CNS structure and many other physiological processes. The role 
of neuroglia in the many pathologies of the nervous system, including some mental illness, epilepsy 
and neurodegenerative diseases, is also defined. Neuroglia include astrocytes, oligodendrocytes, 
Schwann cells, NG2-glia and microglia (Giordano-Santini et al., 2016). Astrocytes interact with 
neurons, blood vessels and many structures of the nervous system and are involved in synaptic 
transmission. The complex astrocyte-neurons-blood vessel is generally known as a neurovascular 
unit (NVU) of the blood-brain barrier. Oligodendrocytes in the CNS and Schwann cells in the 
peripheral nervous system produce myelin, which provides transmission speed along axons. In 
addition, these cells provide trophic support and affect the structure of axons (von Bernhardi et al., 
2016; Mukhamedshina et al., 2019). At the periphery, Schwann cells provide the regeneration of 
axons and neuromuscular junctions. NG2-glia cells are precursors of oligodendrocytes and 
astrocytes, they provide remyelination in case of some neurodegenerative diseases and can also 
modulate neuron properties and activity. Microglia are CNS immune cells, which provide neuron 
protection against various pathogenic factors (von Bernhardi et al., 2016; Akhmetzyanova et al., 
2018). 
2 Classification of extracellular vesicles 
There are three types of EVs that differ in the mechanism of release into the intercellular space, in 
size and cargo: exosomes, microvesicles and apoptotic bodies (Hessvik and Llorente, 2018). 
Exosomes are the smallest EVs, of 30 to 100 nm in diameter, which are formed inside endosomal 
organelles called multivesicular bodies (MVBs). MVBs were initially regarded as prelysosomal 
structures participating in protein degradation. However, new studies showed that MVBs are 
involved in the intra- and intercellular turnover of molecules (Kawikova and Askenase, 2015). The 
release of exosomes occurs in several stages: formation of intraluminal vesicles within MVBs, 
transport of MVBs to the plasma membrane and fusion of MVBs with the plasma membrane 
(Hessvik and Llorente, 2018). MVBs can also fuse with lysosomes to degrade the content (Raposo 
and Stoorvogel, 2013). 
Microvesicles (MVs) are released directly from the plasma membrane and are 100 to 1000 nm in 
diameter (Raposo and Stoorvogel, 2013). MV formation occurs as a result of the 
aminophospholipid translocase-mediated dynamic redistribution of phospholipids and following 
constriction of the actin cytoskeleton due to the actin—myosin interaction (Akers et al., 2013). 
Apoptotic bodies are 50 nm to 5 μm in diameter (Rufino-Ramos et al., 2017) and are released only 
in advanced stages of apoptosis by caspase-mediated cleavage (Todorova et al., 2017). 
The main mechanism to transfer EV cargo into recipient cells is endocytosis. There are many ways 
of endocytosis, including micropynocytosis, phagocytosis, caveolin-mediated, lipid-raft mediated 
and clathrin-dependent endocytosis. Proteins and glycoproteins presented on the surface of both 
EVs and target cells can affect the uptake mechanism (Rufino-Ramos et al., 2017). In this review, 
we will consider exosomes and microvesicles, their potential in the diagnosis and treatment of CNS 
diseases. 
3 Exosome and microvesicle cargo 
Depending on the type of parental cell, exosomes and MVs may have different content including 
bioactive molecules, membrane receptors, proteins, lipids, and genetic material that can be 
transported into target cells (Merchant et al., 2017; Rufino-Ramos et al., 2017; Todorova et al., 
2017). Modern proteomic methods allowed analyzing the protein profile of exosomes and MVs. It 
has been found that exosomes and MVs contain both constitutive proteins found in cells of different 
origin and unique proteins, the presence of which depends on cell type and the microenvironment 
conditions. Unique proteins serve as potential biomarkers for diagnosis of various diseases 
(Haraszti et al., 2016). The proteomic profile of MVs and their parental cell has significant 
homology, in contrast to exosome proteomic profile, which has significant differences from the 
parental cell. Exosomes contain extracellular matrix proteins, heparin-binding proteins, receptors, 
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immune response and cell adhesion proteins, while MVs are enriched in proteasomes, endoplasmic 
reticulum proteins and mitochondria (Haraszti et al., 2016). Most proteins of exosomes and MVs 
are involved in their biogenesis, for example, tetraspanins, Rab proteins and endosomal sorting 
complex required for transport (ESCRT), which is the main engine of exosome biogenesis (Kalluri 
and LeBleu, 2016; Rufino-Ramos et al., 2017). 
Exosomes and MVs also differ in lipid content. Glycolipids and free fatty acids predominate in 
exosomes, and the lipid composition of MVs is rich in ceramides and sphingomyelins (Haraszti et 
al., 2016). The lipid composition of exosomes and MVs, in contrast to their parental cells, is 
distinguished by a high content of phosphatidylserine, which is a determinant for vesicle entry into 
target cells (Record et al., 2018). The entry capacity is also determined by surface receptors and 
ligands of exosomes and MVs (Rufino-Ramos et al., 2017). Exosomes and MVs can contain a wide 
range of genetic material: chromosomal DNA, mitochondrial DNA, single-stranded and double-
stranded DNA encoding messenger RNAs (mRNAs) and non-coding RNAs (long noncoding 
RNAs, microRNAs, and circular RNAs) (Kalluri and LeBleu, 2016; Xu et al., 2016; Kim et al., 
2017). Exosome and MV nucleic acids are potential biomarkers for the diagnosis of many diseases 
(Kinoshita et al., 2017; Szabo and Momen-Heravi, 2017). 
4 Exosomes and microvesicles in normal physiology and CNS diseases 
It is known that exosomes and MVs mediate the interaction of nervous system cells between 
themselves and glial cells, as well as the communication of peripheral organs with the CNS (Batiz 
et al., 2015; Kumar et al., 2018). Neurons, astrocytes, oligodendrocytes and microglial cells release 
EVs and exchange signal molecules through them (Bakhti et al., 2011; Goetzl et al., 2016a; Sun et 
al., 2017; Vinuesa et al., 2018). It is assumed that neural exosome cargo modulates local synaptic 
transmission. For example, it was found out that neural exosomes released after activation of 
glutamatergic synapses merge only with neurons, providing interneuronal communication. Thus, 
exosome and MV cargo can affect the interneuronal communication and synapse activity (Chivet et 
al., 2014; Lu and Xu, 2016). 
In case of CNS diseases, such as neurodegenerative, neuroinflammatory diseases and brain tumors, 
exosomes and MVs, on the one hand, can remove toxic proteins and aggregates from the affected 
cells, and on the other, distribute pathogenic agents to healthy cells (Rufino-Ramos et al., 2017; 
Sardar Sinha et al., 2018).  
Exosomes carrying a prion protein (PrPC) on the surface play a protective role in beta-amyloid 
(Aβ)-mediated neurodegeneration. The prion protein on the surface of neuronal cells acts as a Aβ 
receptor which activates neurotoxic signaling. However, as part of exosome cargo, PrPC binds to 
the neurotoxic Aβ oligomer and contributes to its fibrillation and detoxification (Falker et al., 2016). 
Exosomes and MVs also contribute to angiogenesis, coagulopathy, and metastasis, in particular in 
CNS cancer (Kumar et al., 2018). The ability of exosomes and MVs to overcome BBB allows them 
to spread in body fluids and reach distant tissues, aggravating nervous system disease pathogenesis 
(Selmaj et al., 2017). Exosomes and MVs were shown to contribute to the proliferation of 
superoxide dismutase 1 (SOD1) and RNA-binding protein FUS in amyotrophic lateral sclerosis 
(ALS) (Sproviero et al., 2018), as well as TAR DNA-binding protein 43 (TDP-43) in 
frontotemporal lobar degeneration (FTLD) and ALS (Feneberg et al., 2014; Iguchi et al., 2016). It 
was found that TDP-43 exhibits higher toxicity as exosome cargo than in free form (Feiler et al., 
2015). Exosomes and MVs also contribute to the spread of huntingtin expansion in Huntington's 
disease (Jeon et al., 2016), α-synuclein in Parkinson's disease (Ngolab et al., 2017), tau protein in 
Alzheimer's disease and some other neurodegenerative diseases (Shi et al., 2016; Wang et al., 





5 The use of exosomes and microvesicles in the diagnosis of CNS diseases 
The effectiveness of CNS disease treatment largely depends on the early diagnosis which can be 
achieved by the development of new molecular methods, including EV analysis methods (Hirshman 
et al., 2016). An important feature for diagnosis is that various inflammatory and signaling 
molecules, including RNA and pathogenic proteins, are selectively packaged in exosomes 
(Harischandra et al., 2018). The EV-based diagnostic approach is particularly relevant in those CNS 
diseases, for which direct access to the affected tissues for subsequent molecular analysis is 
difficult. However, to obtain brain cell-released exosomes from various biological fluids is possible 
due to their ability to pass through the BBB (Manek et al., 2018). For diagnostic use, EVs can be 
isolated from many body fluids, such as plasma, urine, cerebrospinal fluid, saliva, amniotic fluid 
and bile (Ko et al., 2016; Manek et al., 2018). However, EV small size and labor-intensive sample 
preparation limit the widespread use of EVs in diagnosis. 
As noted, EV cargo may differ in normal physiological condition and in pathologies. A study of 
cerebrospinal fluid (CSF) in patients with Alzheimer's disease (AD) showed that exosome 
trafficking is different in patients with AD compared to control group (Riancho et al., 2017). In 
addition, it is shown that in traumatic brain injury, the size of secreted exosomes and MVs differs. If 
in the control CSF samples EVs were 99–104 nm in size, then after a traumatic injury their size 
decreased to 74–98 nm. The total amount of EVs also increased and the proportion of some proteins 
changed (Manek et al., 2018). 
Involved in neurodegenerative disease pathogenesis proteins are identified in exosomes and MVs 
isolated from body fluids (most of all blood plasma and CSF). So, α-synuclein (Shi et al., 2014; 
Stuendl et al., 2016) and Leucine-rich repeat kinase 2 (LRRK2) (Fraser et al., 2013) in Parkinson's 
disease (PD), tau protein in asthma and PD spontaneous manifestation (Shi et al., 2016) are 
proposed to use as biomarkers. In chronic traumatic encephalopathy, which occurs as a result of 
repeated blows to the head and is more common in athletes, elevated levels of tau protein in plasma 
exosomes are observed (Stern et al., 2016). In patients with AD and frontotemporal dementia 
(FTD), synaptic dysfunction, which occurs in the early stages as a result of functional synaptic 
protein level decrease, is observed. Analysis of plasma neuron-derived exosomes showed that the 
level of synaptophysin, synaptopodin, synaptotagmin-2 and neurogranin proteins in patients is 
significantly less than in control group. Moreover, its level correlates with the patient's cognitive 
functioning, so it can be used as indicators of disease progression (Goetzl et al., 2016b). Similar 
results were observed in the study of presynaptic proteins neuronal pentraxin 2 (NPTX2), neurexin 
2a (NRXN2a) and corresponding them postsynaptic proteins GluA4-containing glutamate 
(AMPA4) receptor and neuroligin 1 (NLGN1), which enhance excitatory synaptic activity (Goetzl 
et al., 2018). 
Tumor cell-released EVs, called oncosomes, which contain oncogenic signals (proteins or 
transcripts with oncogenic functions) and tumor antigens are also described. The number of 
oncosomes in the patient's biological fluids increases as the disease progresses, so they can be used 
in the diagnosis of CNS tumors (Minciacchi et al., 2015a; Minciacchi et al., 2015b). 
Extracellular RNAs are most frequently mentioned as a potential biomarker of diseases. Today, 
extracellular RNAs contained in neuronal cell-derived exosomes and MVs are used as biomarkers 
to diagnose CNS tumors neurological, neurodegenerative and mental diseases. (Rao et al., 2013). 
Circular RNA (сircRNAs), microRNA (miRNA), piwi-interacting RNA (piRNA) and long non-
coding RNAs (lncRNAs) are essential for maintaining cellular homeostasis. RNA regulation 
disruption and various pathological conditions are interrelated, then changes in RNA expression 
levels may indicate various diseases. For example, circulating U2 fragments of small nuclear RNAs 
have been proposed as a biomarker for primary CNS lymphoma, the expression levels of lncRNAs 
RP11-462G22.1, PCA3 and Sox2OT are associated with PD and AD (Gui et al., 2015), NEAT1 – 
with Huntington's Disease (Lu and Xu, 2016). 
Micro RNAs play a special role in the contraction and progression of many neurodegenerative 
diseases. Today a significant number of investigations aimed at finding potential biomarkers 
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describes microRNAs and its diagnostic potential. MiR-195, miR-24 and miR-19b isolated from 
plasma exosomes and MVs are closely related to neuronal apoptosis, regeneration and 
neurodegenerative processes in PD. In patients with PD, decreased miR-19b level and increased 
miR-195 and miR-24 levels were observed (Cao et al., 2017). The results of another study describe 
changes in the expression of other miRNAs, and it is shown that miR-1 and miR-19b-3p levels in 
patients with PD are less than normal, miR-153, miR-409-3p, miR-10a-5p and let-7g-3p are higher 
than normal (Gui et al., 2015). 
The investigation of CSF miRNA profile of patients with AD showed that miR-16-5p, miR-125b-
5p, miR-451a and miR-605-5p expression in patients with early disease onset differs from the 
control group. In late-onset cohort, similar results are observed, however, the expression level of 
miR-16-5p is not different from the control group, the authors suggest this may be due to age-
related changes in miRNA expression (McKeever et al., 2018). For mesial temporal lobe epilepsy 
with hippocampal sclerosis exosomal miR-3613-5p, miR-4668-5p, miR-8071, miR-197-5p, miR-
4322 and miR-6781-5p diagnosis were also been proposed. Moreover, miR-8071 which correlates 
with seizure severity has the best diagnostic value (Yan et al., 2017). 
6 The use of exosomes and microvesicles in CNS disease treatment 
CNS damage can be caused by various factors, including vascular disease, injures, infectious and 
hereditary diseases. For example, in case of ischemia, inadequate tissue oxygenation leads to 
prolonged hypoxia, depletion of energy reserves in neurons and glial cells. This causes an energy-
dependent membrane ion-pump function decreases, membrane potential loss and, as a result, cell 
damage and cell death (Pratt and McPherson, 1997). And, as a consequence of this, ischemic stroke 
can happen, which may lead to BBB damage and normal neuron functioning disruption (Jiang et al., 
2018). Head injuries often cause neurological disorders (Wright, 2017), CNS inflammatory 
response (Russo and McGavern, 2016), and can accelerate neurodegeneration and increase the risk 
of AD, PD development (McKee and Daneshvar, 2015). Some infectious agents, causing 
encephalitis (Venkatesan and Murphy, 2018), neuroborreliosis, neurosyphilis (Halperin, 2018), 
streptococcal meningoencephalitis (Gres et al., 2019), can also overcome BBB and lead to acute 
inflammation, changes in the brain immune cells and neuron damage. Some lysosomal storage 
diseases can also lead to neurodegeneration, causing accumulation of pathogenic compounds in 
nerve cells, such as cholesterol and sphingolipids in Niemann-Pick disease (Strauss et al., 2010), 
GM2 ganglioside in Tay-Sachs disease (Solovyeva et al., 2018) and Sandhoff disease (Hooper et 
al., 2017). 
The main limitation in the treatment of nervous system diseases is the selective permeability of the 
BBB. Conventional treatment methods involve therapeutic agent delivery using invasive methods, 
including neurosurgery (Timbie et al., 2015), BBB osmotic opening (Bhattacharjee et al., 2001) etc. 
However, such methods result in reduction in the treatment effectiveness and risks for patients. 
EVs are a promising vector for therapeutic agent delivery into the nervous system, as they are 
protected from degradation, retain their original state, and, most importantly, are able to overcome 
the BBB (Kourembanas, 2015). In addition, it was found that brain endothelial cell-released 
exosomes help white blood cells to overcome the BBB. Exosomes are able to transfer claudin-5 
(CLN-5) protein to the surface of leukocytes, which provides tight contacts between cells and make 
up the BBB. With the help of CLN-5, leukocytes can pass BBB using “zipper mechanism” (Paul et 
al., 2016). 
The use of exosomes and MVs is a promising alternative to cell therapy, which can prevent some 
side effects, such as cell oncogenic transformation, undesirable differentiation etc (Chulpanova et 
al., 2018b). At the same time, EVs have several advantages noted during the cell therapy. First, their 
use prevents the risk of transplantation of cells with damaged DNA, which is one of the main cell 
therapy disadvantages. Secondly, EVs are small and easily circulate in the blood, while large cells 
can lead to blockage of vessels. Third, the use of EVs makes it possible to distribute therapeutic 
agents much better, and also to reach CNS (Phinney and Pittenger, 2017). Therapeutic molecules 
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inside EVs are protected by natural lipid bilayer, which ensures stability, biocompatibility, low 
immunogenicity, ability to overcome body biological barriers (for example, BBB), as well as 
targeted drug delivery ability (Rufino-Ramos et al., 2017). 
Despite promising prospects for the use of EVs, there are a number of limitations that need to be 
considered when constructing treatment strategies. It was found that EVs may contribute to the 
progression of certain diseases by spreading pathogenic agents into healthy cells (Bakhshandeh et 
al., 2017). 
Native MSCs-derived exosomes are used for the regeneration of nervous tissue. For example, the 
exosomes were shown to stimulate the restoration of damaged axons. It is believed that this effect is 
due to growth factors such as vascular endothelial growth factor (VEGF), hepatocyte growth factor 
(HGF), epidermal growth factor (EGF), brain-derived neurotrophic factor (BDNF) and 
neurotrophin-3 (NT-3), which are necessary for neuron growth and recovery (Lopez-Verrilli et al., 
2016). Similar results were shown for native exosomes from Schwann cells (Lopez-Verrilli et al., 
2013). 
Constant inflammatory processes lead to chronic neurodegeneration, which is associated with the 
activation of microglia. Microglia can play a dual role, on the one hand, it responds to certain 
stimuli with a set of pro-inflammatory molecules, on the other hand, it cleans damaged cells and 
stimulates tissue repair. The use of native MSCs-released MVs leads to a modulation of microglia, 
reducing the transcription of genes associated with inflammation and thereby preventing microglia 
activation (Jaimes et al., 2017). EVs can be used in therapy both in their native form and loaded 
with specific molecules using various methods (Table 1). 
Modification can be carried out after EV isolation or by changing parental cells (Rufino-Ramos et 
al., 2017). Native EVs typically express lipids, cell adhesion molecules and ligands that naturally 
target specific types of recipient cells. Molecules that determine targeting can also be changed, most 
often by parental cell modification with genes encoding the molecule of interest (Luan et al., 2017). 
For example, targeted drug delivery with EVs to nervous system cells can be achieved by EV 
surface modification with a rabies virus glycoprotein, by which EVs selectively target neurons and 
endothelial brain cells by binding to nicotinic acetylcholine receptors (Cui et al., 2018). 
Parkinson's disease 
Parkinson's disease is the second most common neurodegenerative disease (Tomiyama et al., 2015). 
PD is characterized by the presence of Lewy bodies formed due to α-synuclein aggregation and the 
death of dopamine neurons (Fan et al., 2017). Dopamine deficiency leads to motor impairment, 
particularly tremor, rigidity and bradykinesia (Tysnes and Storstein, 2017). It is known that 
oxidative stress aggravates neurodegeneration in PD patients. Intranasal administration of exosomes 
loaded with catalase into PD model mice resulted in significant neuroprotective effect. Exosomes 
isolated from monocytes and macrophages were used in the work, this vesicles avoid capture by the 
immune cells, are able to overcome the BBB and effectively bind with brain cells. Various methods 
were used for catalase loading, the most effective were the use of saponin, sonication and extrusion 
(Haney et al., 2015; Kojima et al., 2018). Exosomes, isolated from stem cells from human 
exfoliated deciduous teeth (SHEDs) 3D culture, possess neuroprotective potential and prevent 
apoptosis in dopaminergic neurons by approximately 80%. It is noteworthy that exosomes obtained 
from cells cultured under standard conditions do not show such an effect (Jarmalaviciute et al., 
2015). 
Alzheimer's disease 
Alzheimer's disease is a degenerative disease of the CNS, one of the most common causes of 
dementia, characterized by the formation of two major protein aggregates: senile (amyloid) plaques 
and neurofibrillary tangles (NFTs), which are involved in processes leading to progressive 
neurodegeneration and death (Thei et al., 2018). Senile plaques are formed by the deposition of Aβ 
peptide fibrils in the human brain is the main component of paired helical filaments (PHFs), which 
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form compact filamentous structures called neurofibrillary tangles. In vitro experiments with 
hippocampal cells have shown a relationship between amyloid fibrils and signaling pathways which 
cause excessive phosphorylation of tau protein, which leads to destabilization of microtubules and 
axonal transport blocking (Dhiman et al., 2019). It was also shown that abnormal phosphorylation 
of tau protein involves two protein kinases: cyclin-dependent kinase 5 (Cdk5) and glycogen 
synthase kinase 3β (GSK3β). In vitro studies of brain cells and neuroblastoma cells showed that 
Cdk5 is involved in the processes of cortex maturation and neuron migration, and also plays an 
important role in normal brain development. Deregulation of this protein kinase leads to excessive 
tau protein phosphorylation, thereby causing a sequence of molecular events leading to neuron 
degeneration (Liu et al., 2016). A number of studies showed that oxidative stress is a major factor in 
normal signaling pathway altering in neurons, which leads to their biochemical, structural 
abnormalities and degeneration. The main genes involved in the development of Alzheimer's 
disease encode proteins such as APP, presenilins 1 and 2, alpha-2-macroglobulin and apoliprotein E 
(Qu et al., 2019). 
MicroRNAs play an important role in the regulation of various inflammatory responses. It is known 
that miR-21 controls the balance between pro-inflammatory, immunoregulatory and anti-
inflammatory reactions. Dysregulation of miR-21 causes a chronic inflammation. Hypoxia-
preconditioned MSCs have increased miR-21 expression. Injection of exosomes isolated from 
hypoxia-preconditioned MSCs to AD model animals (APP/PS1) led to improvement in their 
memory and ability to learn, and also reduced the accumulation of Aβ-peptide. The results 
confirmed the ability of native MSC-derived exosomes without surface molecule modification to 
penetrate into the CNS (Cui et al., 2018). In AD glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) glycolytic enzyme is involved in neurodegenerative processes and in apoptotic cell death 
(El Kadmiri et al., 2014). The administration of GAPDH siRNA into mice using exosomes isolated 
from autologous dendritic cells modified with neuron-specific RVG peptide for targeting resulted in 
specific gene knockdown in neurons, microglia, and oligodendrocytes in the brain. Exosomes were 
loaded with exogenous siRNA by electroplating (Alvarez-Erviti et al., 2011). 
Huntington's Disease 
Huntington's disease is an autosomal dominant neurodegenerative disease which leads to impaired 
motor and cognitive functions. Neurodegeneration is caused by the accumulation of mutant 
huntingtin protein, which negatively affects many cell processes. Mutant protein occurs due to CAG 
repeats, the CAG repeat length is inversely correlated with the disease severity and age of onset 
(Pagan et al., 2017). It is known that mutations in the huntingtin protein are the main cause of the 
Huntington's disease. Hydrophobically modified small interfering RNAs (hsiRNAs) aimed at 
huntingtin mRNA were used to eliminate the toxic protein. During joint incubation, hsiRNAs were 
loaded into exosomes isolated from the human U87 glioblastoma cell. It was shown that the use of 
such exosomes improved hsiRNA spread in the brain of model animals, due to which huntingtin 
gene silence was achieved. The authors recognize that use of glioblastoma cell-derived exosomes 
can provoke tumor formation, due to which it is necessary to optimize methods for obtaining 
exosome from other cell types in order to introduce this approach into clinical practice (Didiot et al., 
2016). 
Epilepsy 
Epilepsy is a widespread chronic neurological disorder characterized by recurrent convulsive 
seizures. Variety of brain damages, including injuries, CNS infections and tumors can lead to 
epilepsy (Vezzani et al., 2016). The seizures cause an increase in extracellular glutamate level 
which contributes to cell damage and changes in neuronal signaling (Barker-Haliski and White, 
2015). Epilepsy can result in mental disorders and mental retardation (Guerreiro, 2016). 
Chronic hippocampus dysfunction is another one consequence of epilepsy. In order to prevent it, the 
use of exosomes from human bone marrow-derived MSCs, which have strong anti-inflammatory 
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and neuroprotective properties was proposed. Intranasal administration of exosomes to model mice 
led to a neuronal loss decrease, inflammation reduction, normal neurogenesis maintenance, 
cognitive functions and memory preservation (Long et al., 2017). 
Multiple sclerosis 
Multiple sclerosis is a chronic inflammatory CNS disease leading to demyelination and 
neurodegeneration (Correale et al., 2017). MS etiology remains unclear, but it is assumed that MS is 
an autoimmune disease. Progressive MS leads to the loss of axons and trophic support (Nicholas 
and Rashid, 2013). It was shown that native exosomes and MVs from human periodontal ligament 
stem cells (hPDLSCs) exhibit regenerative and immunomodulating properties in the treatment of 
multiple sclerosis. After their administration to MS model mice a decrease in proinflammatory 
cytokines interleukin 17 (IL-17), interferon γ (IFN-γ), IL-1β, IL-6, tumor necrosis factor α (TNF-α), 
induction of anti-inflammatory IL-10 and expression attenuation of signal transducer and activator 
of transcription 1 (STAT1), p53, Caspase 3 and Bcl-2-associated X protein (BAX), which are 
associated with cell apoptosis were observed (Rajan et al., 2016). 
Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis is characterized by the degeneration of the upper and lower motor 
neurons, which leads to muscle weakness, convulsions, paralysis, and death (Hardiman et al., 2017). 
The causes of ALS remain unknown, but the genes associated with the disease have been identified 
(Chia et al., 2018). Neuronal cytoplasmic inclusions of TDP-43, FUS, C9orf72, TDP-43 are 
characterized of ALS (Saberi et al., 2015). The use of native exosomes from adipose tissue-derived 
stem cells (ADSCs) on mouse neuronal cell culture ALS model showed dismutase 1 (SOD1) 
aggregation relief, it is assumed that the effect is achieved due to the restoration of mitochondrial 
functions (Lee et al., 2016). 
Conclusion 
Exosomes and microvesicles are membrane nanoparticles of endosomal and membrane origin, 
which provide intercellular communication through the transport of biological molecules. It was 
found that exosomes and MVs are released by many CNS cells and play an important role in its 
functioning, as well as contribute to the spread of pathogenic agents in various diseases. Due to the 
identification of novel biomarkers we face the prospects of exosomes and MVs application for the 
early diagnosis of the nervous system diseases. The ability to overcome the blood-brain barrier, 
protect therapeutic agents from degradation, lack of immunoreactivity, biosafety and the possibility 
of targeted delivery make exosomes and MVs promising tools for use in clinical practice for cell-
mediated therapy of CNS diseases. 
Conflicts of interest 
The authors declare no conflicts of interest. 
Acknowledgments 
This study was supported by the Russian Government Program of Competitive Growth of Kazan 
Federal University. Albert A. Rizvanov was supported by state assignment 20.5175.2017/6.7 of the 




Table 1. Examples of the use of extracellular vesicles for the treatment of CNS diseases  





macrophages loaded with 
catalase 
Neuroprotection 
(Haney et al., 
2013; Haney et 
al., 2015; Kojima 
et al., 2018) 
Exosomes from MSC 3D 
culture 
Neuroprotection, protection 





with GDNF encoding 
plasmid 
Neuroprotection, protection 
of dopaminergic neurons 
(Zhao et al., 2014) 
Alzheimer's 
disease 




Memory and learning ability 
improvement, Aβ-peptide 
accumulation reduction 
(Cui et al., 2018) 
Exosomes from dendritic 
cells with GAPDH 
siRNA and RVG peptide 








Exosomes from human 
U87 glioblastoma cell 
with huntingtin-targeted 
siRNA  
Huntingtin gene knockdown 
(Didiot et al., 
2016) 
Epilepsy 
Native exosomes from 
bone marrow MSCs 
Neuronal loss and 
inflammation reduction, 
neurogenesis normalization, 
preservation of cognitive 
functions and memory 
(Long et al., 
2017) 
Multiple sclerosis 
Native exosomes and 
MVs from hPDLSCs 
Regeneration and 
immunomodulation 
(Rajan et al., 
2016) 








Native exosomes from 
MSCs 
SOD1 aggregation relief (Lee et al., 2016) 
References 
Akers JC, Gonda D, Kim R, Carter BS, Chen CC (2013) Biogenesis of extracellular vesicles (EV): 
exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. Journal of neuro-oncology 
113:1-11. 
Akhmetzyanova ER, Mukhamedshina YO, Zhuravleva MN, Galieva LR, Kostennikov AA, 
Garanina EE, Rizvanov AA (2018) Transplantation of Microglia in the Area of Spinal Cord Injury 
in an Acute Period Increases Tissue Sparing, but Not Functional Recovery. Frontiers in cellular 
neuroscience 12:507. 
Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ (2011) Delivery of siRNA to the 
mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29:341-345. 
11 
 
Bakhshandeh B, Kamaleddin MA, Aalishah K (2017) A Comprehensive Review on Exosomes and 
Microvesicles as Epigenetic Factors. Current stem cell research & therapy 12:31-36. 
Bakhti M, Winter C, Simons M (2011) Inhibition of myelin membrane sheath formation by 
oligodendrocyte-derived exosome-like vesicles. J Biol Chem 286:787-796. 
Barker-Haliski M, White HS (2015) Glutamatergic Mechanisms Associated with Seizures and 
Epilepsy. Cold Spring Harbor perspectives in medicine 5:a022863. 
Batiz LF, Castro MA, Burgos PV, Velasquez ZD, Munoz RI, Lafourcade CA, Troncoso-Escudero 
P, Wyneken U (2015) Exosomes as Novel Regulators of Adult Neurogenic Niches. Frontiers in 
cellular neuroscience 9:501. 
Bhattacharjee AK, Nagashima T, Kondoh T, Tamaki N (2001) Quantification of early blood-brain 
barrier disruption by in situ brain perfusion technique. Brain research Brain research protocols 
8:126-131. 
Cao XY, Lu JM, Zhao ZQ, Li MC, Lu T, An XS, Xue LJ (2017) MicroRNA biomarkers of 
Parkinson's disease in serum exosome-like microvesicles. Neurosci Lett 644:94-99. 
Caruso Bavisotto C, Scalia F, Marino Gammazza A, Carlisi D, Bucchieri F, Conway de Macario E, 
Macario AJL, Cappello F, Campanella C (2019) Extracellular Vesicle-Mediated Cell(-)Cell 
Communication in the Nervous System: Focus on Neurological Diseases. Int J Mol Sci 20. 
Chia R, Chio A, Traynor BJ (2018) Novel genes associated with amyotrophic lateral sclerosis: 
diagnostic and clinical implications. The Lancet Neurology 17:94-102. 
Chivet M, Hemming F, Pernet-Gallay K, Fraboulet S, Sadoul R (2012) Emerging role of neuronal 
exosomes in the central nervous system. Frontiers in physiology 3:145. 
Chivet M, Javalet C, Laulagnier K, Blot B, Hemming FJ, Sadoul R (2014) Exosomes secreted by 
cortical neurons upon glutamatergic synapse activation specifically interact with neurons. J 
Extracell Vesicles 3:24722. 
Choo YW, Kang M, Kim HY, Han J, Kang S, Lee JR, Jeong GJ, Kwon SP, Song SY, Go S, Jung 
M, Hong J, Kim BS (2018) M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer 
Efficacy of Immune Checkpoint Inhibitors. ACS Nano 12:8977-8993. 
Chulpanova DS, Kitaeva KV, James V, Rizvanov AA, Solovyeva VV (2018a) Therapeutic 
Prospects of Extracellular Vesicles in Cancer Treatment. Frontiers in immunology 9:1534. 
Chulpanova DS, Kitaeva KV, Tazetdinova LG, James V, Rizvanov AA, Solovyeva VV (2018b) 
Application of Mesenchymal Stem Cells for Therapeutic Agent Delivery in Anti-tumor Treatment. 
Front Pharmacol 9:259. 
Correale J, Gaitan MI, Ysrraelit MC, Fiol MP (2017) Progressive multiple sclerosis: from 
pathogenic mechanisms to treatment. Brain : a journal of neurology 140:527-546. 
Cui GH, Wu J, Mou FF, Xie WH, Wang FB, Wang QL, Fang J, Xu YW, Dong YR, Liu JR, Guo 
HD (2018) Exosomes derived from hypoxia-preconditioned mesenchymal stromal cells ameliorate 
cognitive decline by rescuing synaptic dysfunction and regulating inflammatory responses in 
APP/PS1 mice. FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology 32:654-668. 
Dhiman K, Blennow K, Zetterberg H, Martins RN, Gupta VB (2019) Cerebrospinal fluid 
biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis. Cellular and 
molecular life sciences : CMLS. 
12 
 
Didiot MC, Hall LM, Coles AH, Haraszti RA, Godinho BM, Chase K, Sapp E, Ly S, Alterman JF, 
Hassler MR, Echeverria D, Raj L, Morrissey DV, DiFiglia M, Aronin N, Khvorova A (2016) 
Exosome-mediated Delivery of Hydrophobically Modified siRNA for Huntingtin mRNA Silencing. 
Mol Ther 24:1836-1847. 
El Kadmiri N, Slassi I, El Moutawakil B, Nadifi S, Tadevosyan A, Hachem A, Soukri A (2014) 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease. Pathologie-
biologie 62:333-336. 
Falker C, Hartmann A, Guett I, Dohler F, Altmeppen H, Betzel C, Schubert R, Thurm D, Wegwitz 
F, Joshi P, Verderio C, Krasemann S, Glatzel M (2016) Exosomal cellular prion protein drives 
fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity. J Neurochem 
137:88-100. 
Fan CH, Lin CY, Liu HL, Yeh CK (2017) Ultrasound targeted CNS gene delivery for Parkinson's 
disease treatment. J Control Release 261:246-262. 
Feiler MS, Strobel B, Freischmidt A, Helferich AM, Kappel J, Brewer BM, Li D, Thal DR, Walther 
P, Ludolph AC, Danzer KM, Weishaupt JH (2015) TDP-43 is intercellularly transmitted across 
axon terminals. J Cell Biol 211:897-911. 
Feneberg E, Steinacker P, Lehnert S, Schneider A, Walther P, Thal DR, Linsenmeier M, Ludolph 
AC, Otto M (2014) Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. 
Amyotrophic lateral sclerosis & frontotemporal degeneration 15:351-356. 
Fraser KB, Moehle MS, Daher JP, Webber PJ, Williams JY, Stewart CA, Yacoubian TA, Cowell 
RM, Dokland T, Ye T, Chen D, Siegal GP, Galemmo RA, Tsika E, Moore DJ, Standaert DG, 
Kojima K, Mobley JA, West AB (2013) LRRK2 secretion in exosomes is regulated by 14-3-3. Hum 
Mol Genet 22:4988-5000. 
Galieva LR, James V, Mukhamedshina YO, Rizvanov AA (2019) Therapeutic Potential of 
Extracellular Vesicles for the Treatment of Nerve Disorders. Front Neurosci 13:163. 
Garcia-Romero N, Carrion-Navarro J, Esteban-Rubio S, Lazaro-Ibanez E, Peris-Celda M, Alonso 
MM, Guzman-De-Villoria J, Fernandez-Carballal C, de Mendivil AO, Garcia-Duque S, Escobedo-
Lucea C, Prat-Acin R, Belda-Iniesta C, Ayuso-Sacido A (2017) DNA sequences within glioma-
derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral 
blood of patients. Oncotarget 8:1416-1428. 
Giordano-Santini R, Linton C, Hilliard MA (2016) Cell-cell fusion in the nervous system: 
Alternative mechanisms of development, injury, and repair. Seminars in cell & developmental 
biology 60:146-154. 
Goetzl EJ, Abner EL, Jicha GA, Kapogiannis D, Schwartz JB (2018) Declining levels of 
functionally specialized synaptic proteins in plasma neuronal exosomes with progression of 
Alzheimer's disease. FASEB journal : official publication of the Federation of American Societies 
for Experimental Biology 32:888-893. 
Goetzl EJ, Mustapic M, Kapogiannis D, Eitan E, Lobach IV, Goetzl L, Schwartz JB, Miller BL 
(2016a) Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer's disease. FASEB 
journal : official publication of the Federation of American Societies for Experimental Biology 
30:3853-3859. 
Goetzl EJ, Kapogiannis D, Schwartz JB, Lobach IV, Goetzl L, Abner EL, Jicha GA, Karydas AM, 
Boxer A, Miller BL (2016b) Decreased synaptic proteins in neuronal exosomes of frontotemporal 
dementia and Alzheimer's disease. FASEB journal : official publication of the Federation of 
American Societies for Experimental Biology 30:4141-4148. 
13 
 
Gres V, Kolter J, Erny D, Henneke P (2019) The role of CNS macrophages in streptococcal 
meningoencephalitis. J Leukoc Biol. 
Guerreiro CA (2016) Epilepsy: Is there hope? The Indian journal of medical research 144:657-660. 
Gui Y, Liu H, Zhang L, Lv W, Hu X (2015) Altered microRNA profiles in cerebrospinal fluid 
exosome in Parkinson disease and Alzheimer disease. Oncotarget 6:37043-37053. 
Halperin JJ (2018) Neuroborreliosis and Neurosyphilis. Continuum 24:1439-1458. 
Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z, Patel T, Piroyan A, Sokolsky M, 
Kabanov AV, Batrakova EV (2015) Exosomes as drug delivery vehicles for Parkinson's disease 
therapy. J Control Release 207:18-30. 
Haney MJ, Zhao Y, Harrison EB, Mahajan V, Ahmed S, He Z, Suresh P, Hingtgen SD, Klyachko 
NL, Mosley RL, Gendelman HE, Kabanov AV, Batrakova EV (2013) Specific transfection of 
inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseases. PLoS 
One 8:e61852. 
Haraszti RA, Didiot MC, Sapp E, Leszyk J, Shaffer SA, Rockwell HE, Gao F, Narain NR, DiFiglia 
M, Kiebish MA, Aronin N, Khvorova A (2016) High-resolution proteomic and lipidomic analysis 
of exosomes and microvesicles from different cell sources. J Extracell Vesicles 5:32570. 
Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, 
van den Berg LH (2017) Amyotrophic lateral sclerosis. Nature reviews Disease primers 3:17071. 
Harischandra DS, Ghaisas S, Rokad D, Zamanian M, Jin H, Anantharam V, Kimber M, 
Kanthasamy A, Kanthasamy AG (2018) Environmental neurotoxicant manganese regulates 
exosome-mediated extracellular miRNAs in cell culture model of Parkinson's disease: Relevance to 
alpha-synuclein misfolding in metal neurotoxicity. Neurotoxicology 64:267-277. 
Hartmann AA, Burg G (1989) [Fulminant acne in Klinefelter syndrome treated with testosterone. A 
side effect of anti-tallness therapy]. Monatsschrift Kinderheilkunde : Organ der Deutschen 
Gesellschaft fur Kinderheilkunde 137:466-467. 
Hessvik NP, Llorente A (2018) Current knowledge on exosome biogenesis and release. Cellular and 
molecular life sciences : CMLS 75:193-208. 
Hirshman BR, Kras RT, Akers JC, Carter BS, Chen CC (2016) Extracellular Vesicles in Molecular 
Diagnostics: An Overview with a Focus on CNS Diseases. Advances in clinical chemistry 76:37-
53. 
Hooper AWM, Alamilla JF, Venier RE, Gillespie DC, Igdoura SA (2017) Neuronal pentraxin 1 
depletion delays neurodegeneration and extends life in Sandhoff disease mice. Hum Mol Genet 
26:661-673. 
Huey R, Hawthorne S, McCarron P (2017) The potential use of rabies virus glycoprotein-derived 
peptides to facilitate drug delivery into the central nervous system: a mini review. Journal of drug 
targeting 25:379-385. 
Iguchi Y, Eid L, Parent M, Soucy G, Bareil C, Riku Y, Kawai K, Takagi S, Yoshida M, Katsuno M, 
Sobue G, Julien JP (2016) Exosome secretion is a key pathway for clearance of pathological TDP-
43. Brain : a journal of neurology 139:3187-3201. 
Jaimes Y, Naaldijk Y, Wenk K, Leovsky C, Emmrich F (2017) Mesenchymal Stem Cell-Derived 
Microvesicles Modulate Lipopolysaccharides-Induced Inflammatory Responses to Microglia Cells. 
Stem Cells 35:812-823. 
14 
 
Jarmalaviciute A, Tunaitis V, Pivoraite U, Venalis A, Pivoriunas A (2015) Exosomes from dental 
pulp stem cells rescue human dopaminergic neurons from 6-hydroxy-dopamine-induced apoptosis. 
Cytotherapy 17:932-939. 
Jeon I, Cicchetti F, Cisbani G, Lee S, Li E, Bae J, Lee N, Li L, Im W, Kim M, Kim HS, Oh SH, 
Kim TA, Ko JJ, Aube B, Oueslati A, Kim YJ, Song J (2016) Human-to-mouse prion-like 
propagation of mutant huntingtin protein. Acta Neuropathol 132:577-592. 
Jiang X, Andjelkovic AV, Zhu L, Yang T, Bennett MVL, Chen J, Keep RF, Shi Y (2018) Blood-
brain barrier dysfunction and recovery after ischemic stroke. Progress in neurobiology 163-
164:144-171. 
Kalluri R, LeBleu VS (2016) Discovery of Double-Stranded Genomic DNA in Circulating 
Exosomes. Cold Spring Harbor symposia on quantitative biology 81:275-280. 
Kawikova I, Askenase PW (2015) Diagnostic and therapeutic potentials of exosomes in CNS 
diseases. Brain research 1617:63-71. 
Kim KM, Abdelmohsen K, Mustapic M, Kapogiannis D, Gorospe M (2017) RNA in extracellular 
vesicles. Wiley interdisciplinary reviews RNA 8. 
Kinoshita T, Yip KW, Spence T, Liu FF (2017) MicroRNAs in extracellular vesicles: potential 
cancer biomarkers. Journal of human genetics 62:67-74. 
Ko J, Carpenter E, Issadore D (2016) Detection and isolation of circulating exosomes and 
microvesicles for cancer monitoring and diagnostics using micro-/nano-based devices. The Analyst 
141:450-460. 
Kojima R, Bojar D, Rizzi G, Hamri GC, El-Baba MD, Saxena P, Auslander S, Tan KR, 
Fussenegger M (2018) Designer exosomes produced by implanted cells intracerebrally deliver 
therapeutic cargo for Parkinson's disease treatment. Nat Commun 9:1305. 
Kourembanas S (2015) Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of 
cell therapy. Annual review of physiology 77:13-27. 
Kumar D, Manek R, Raghavan V, Wang KK (2018) Protein Characterization of Extracellular 
Microvesicles/Exosomes Released from Cytotoxin-Challenged Rat Cerebrocortical Mixed Culture 
and Mouse N2a Cells. Molecular neurobiology 55:2112-2124. 
Lee M, Ban JJ, Kim KY, Jeon GS, Im W, Sung JJ, Kim M (2016) Adipose-derived stem cell 
exosomes alleviate pathology of amyotrophic lateral sclerosis in vitro. Biochem Biophys Res 
Commun 479:434-439. 
Liu SL, Wang C, Jiang T, Tan L, Xing A, Yu JT (2016) The Role of Cdk5 in Alzheimer's Disease. 
Molecular neurobiology 53:4328-4342. 
Long Q, Upadhya D, Hattiangady B, Kim DK, An SY, Shuai B, Prockop DJ, Shetty AK (2017) 
Intranasal MSC-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and 
memory dysfunction after status epilepticus. Proc Natl Acad Sci U S A 114:E3536-E3545. 
Lopez-Verrilli MA, Picou F, Court FA (2013) Schwann cell-derived exosomes enhance axonal 
regeneration in the peripheral nervous system. Glia 61:1795-1806. 
Lopez-Verrilli MA, Caviedes A, Cabrera A, Sandoval S, Wyneken U, Khoury M (2016) 
Mesenchymal stem cell-derived exosomes from different sources selectively promote neuritic 
outgrowth. Neuroscience 320:129-139. 
Lu D, Xu AD (2016) Mini Review: Circular RNAs as Potential Clinical Biomarkers for Disorders 
in the Central Nervous System. Frontiers in genetics 7:53. 
15 
 
Luan X, Sansanaphongpricha K, Myers I, Chen H, Yuan H, Sun D (2017) Engineering exosomes as 
refined biological nanoplatforms for drug delivery. Acta pharmacologica Sinica 38:754-763. 
Manek R, Moghieb A, Yang Z, Kumar D, Kobessiy F, Sarkis GA, Raghavan V, Wang KKW 
(2018) Protein Biomarkers and Neuroproteomics Characterization of Microvesicles/Exosomes from 
Human Cerebrospinal Fluid Following Traumatic Brain Injury. Molecular neurobiology 55:6112-
6128. 
Mathew B, Ravindran S, Liu X, Torres L, Chennakesavalu M, Huang CC, Feng L, Zelka R, Lopez 
J, Sharma M, Roth S (2019) Mesenchymal stem cell-derived extracellular vesicles and retinal 
ischemia-reperfusion. Biomaterials 197:146-160. 
Matsumoto J, Stewart T, Banks WA, Zhang J (2017a) The Transport Mechanism of Extracellular 
Vesicles at the Blood-Brain Barrier. Curr Pharm Des 23:6206-6214. 
Matsumoto J, Stewart T, Sheng L, Li N, Bullock K, Song N, Shi M, Banks WA, Zhang J (2017b) 
Transmission of alpha-synuclein-containing erythrocyte-derived extracellular vesicles across the 
blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and 
progression of Parkinson's disease? Acta neuropathologica communications 5:71. 
McKee AC, Daneshvar DH (2015) The neuropathology of traumatic brain injury. Handbook of 
clinical neurology 127:45-66. 
McKeever PM, Schneider R, Taghdiri F, Weichert A, Multani N, Brown RA, Boxer AL, Karydas 
A, Miller B, Robertson J, Tartaglia MC (2018) MicroRNA Expression Levels Are Altered in the 
Cerebrospinal Fluid of Patients with Young-Onset Alzheimer's Disease. Molecular neurobiology 
55:8826-8841. 
Merchant ML, Rood IM, Deegens JKJ, Klein JB (2017) Isolation and characterization of urinary 
extracellular vesicles: implications for biomarker discovery. Nature reviews Nephrology 13:731-
749. 
Minciacchi VR, Freeman MR, Di Vizio D (2015a) Extracellular vesicles in cancer: exosomes, 
microvesicles and the emerging role of large oncosomes. Seminars in cell & developmental biology 
40:41-51. 
Minciacchi VR et al. (2015b) Large oncosomes contain distinct protein cargo and represent a 
separate functional class of tumor-derived extracellular vesicles. Oncotarget 6:11327-11341. 
Mukhamedshina YO, Gracheva OA, Mukhutdinova DM, Chelyshev YA, Rizvanov AA (2019) 
Mesenchymal stem cells and the neuronal microenvironment in the area of spinal cord injury. 
Neural regeneration research 14:227-237. 
Ngolab J, Trinh I, Rockenstein E, Mante M, Florio J, Trejo M, Masliah D, Adame A, Masliah E, 
Rissman RA (2017) Brain-derived exosomes from dementia with Lewy bodies propagate alpha-
synuclein pathology. Acta neuropathologica communications 5:46. 
Nicholas R, Rashid W (2013) Multiple sclerosis. American family physician 87:712-714. 
Pagan F, Torres-Yaghi Y, Altshuler M (2017) The diagnosis and natural history of Huntington 
disease. Handbook of clinical neurology 144:63-67. 
Paul D, Baena V, Ge S, Jiang X, Jellison ER, Kiprono T, Agalliu D, Pachter JS (2016) Appearance 
of claudin-5(+) leukocytes in the central nervous system during neuroinflammation: a novel role for 
endothelial-derived extracellular vesicles. Journal of neuroinflammation 13:292. 
Phinney DG, Pittenger MF (2017) Concise Review: MSC-Derived Exosomes for Cell-Free 
Therapy. Stem Cells 35:851-858. 
16 
 
Phoolcharoen W, Prehaud C, van Dolleweerd CJ, Both L, da Costa A, Lafon M, Ma JK (2017) 
Enhanced transport of plant-produced rabies single-chain antibody-RVG peptide fusion protein 
across an in cellulo blood-brain barrier device. Plant biotechnology journal 15:1331-1339. 
Pitt JM, Andre F, Amigorena S, Soria JC, Eggermont A, Kroemer G, Zitvogel L (2016) Dendritic 
cell-derived exosomes for cancer therapy. J Clin Invest 126:1224-1232. 
Pratt BM, McPherson JM (1997) TGF-beta in the central nervous system: potential roles in 
ischemic injury and neurodegenerative diseases. Cytokine & growth factor reviews 8:267-292. 
Preston JE, Joan Abbott N, Begley DJ (2014) Transcytosis of macromolecules at the blood-brain 
barrier. Advances in pharmacology 71:147-163. 
Pusic KM, Pusic AD, Kraig RP (2016) Environmental Enrichment Stimulates Immune Cell 
Secretion of Exosomes that Promote CNS Myelination and May Regulate Inflammation. Cellular 
and molecular neurobiology 36:313-325. 
Qu Y, Liu Y, Noor AF, Tran J, Li R (2019) Characteristics and advantages of adeno-associated 
virus vector-mediated gene therapy for neurodegenerative diseases. Neural regeneration research 
14:931-938. 
Radosinska J, Bartekova M (2017) Therapeutic Potential of Hematopoietic Stem Cell-Derived 
Exosomes in Cardiovascular Disease. Advances in experimental medicine and biology 998:221-
235. 
Rajan TS, Giacoppo S, Diomede F, Ballerini P, Paolantonio M, Marchisio M, Piattelli A, Bramanti 
P, Mazzon E, Trubiani O (2016) The secretome of periodontal ligament stem cells from MS 
patients protects against EAE. Sci Rep 6:38743. 
Rao P, Benito E, Fischer A (2013) MicroRNAs as biomarkers for CNS disease. Frontiers in 
molecular neuroscience 6:39. 
Raposo G, Stoorvogel W (2013) Extracellular vesicles: exosomes, microvesicles, and friends. J Cell 
Biol 200:373-383. 
Record M, Silvente-Poirot S, Poirot M, Wakelam MJO (2018) Extracellular vesicles: lipids as key 
components of their biogenesis and functions. Journal of lipid research 59:1316-1324. 
Riancho J, Vazquez-Higuera JL, Pozueta A, Lage C, Kazimierczak M, Bravo M, Calero M, 
Gonalezalez A, Rodriguez E, Lleo A, Sanchez-Juan P (2017) MicroRNA Profile in Patients with 
Alzheimer's Disease: Analysis of miR-9-5p and miR-598 in Raw and Exosome Enriched 
Cerebrospinal Fluid Samples. J Alzheimers Dis 57:483-491. 
Rufino-Ramos D, Albuquerque PR, Carmona V, Perfeito R, Nobre RJ, Pereira de Almeida L (2017) 
Extracellular vesicles: Novel promising delivery systems for therapy of brain diseases. J Control 
Release 262:247-258. 
Russo MV, McGavern DB (2016) Inflammatory neuroprotection following traumatic brain injury. 
Science 353:783-785. 
Saberi S, Stauffer JE, Schulte DJ, Ravits J (2015) Neuropathology of Amyotrophic Lateral 
Sclerosis and Its Variants. Neurologic clinics 33:855-876. 
Sardar Sinha M, Ansell-Schultz A, Civitelli L, Hildesjo C, Larsson M, Lannfelt L, Ingelsson M, 
Hallbeck M (2018) Alzheimer's disease pathology propagation by exosomes containing toxic 
amyloid-beta oligomers. Acta Neuropathol 136:41-56. 
Selmaj I, Mycko MP, Raine CS, Selmaj KW (2017) The role of exosomes in CNS inflammation 
and their involvement in multiple sclerosis. J Neuroimmunol 306:1-10. 
17 
 
Shi M, Liu C, Cook TJ, Bullock KM, Zhao Y, Ginghina C, Li Y, Aro P, Dator R, He C, Hipp MJ, 
Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, Banks WA, Zhang J (2014) Plasma 
exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson's disease. Acta 
Neuropathol 128:639-650. 
Shi M, Kovac A, Korff A, Cook TJ, Ginghina C, Bullock KM, Yang L, Stewart T, Zheng D, Aro P, 
Atik A, Kerr KF, Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, Montine TJ, Banks 
WA, Zhang J (2016) CNS tau efflux via exosomes is likely increased in Parkinson's disease but not 
in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association 
12:1125-1131. 
Solovyeva VV, Shaimardanova AA, Chulpanova DS, Kitaeva KV, Chakrabarti L, Rizvanov AA 
(2018) New Approaches to Tay-Sachs Disease Therapy. Frontiers in physiology 9:1663. 
Sousa C, Pereira I, Santos AC, Carbone C, Kovacevic AB, Silva AM, Souto EB (2017) Targeting 
dendritic cells for the treatment of autoimmune disorders. Colloids and surfaces B, Biointerfaces 
158:237-248. 
Sproviero D, La Salvia S, Giannini M, Crippa V, Gagliardi S, Bernuzzi S, Diamanti L, Ceroni M, 
Pansarasa O, Poletti A, Cereda C (2018) Pathological Proteins Are Transported by Extracellular 
Vesicles of Sporadic Amyotrophic Lateral Sclerosis Patients. Frontiers in neuroscience 12:487. 
Stern RA, Tripodis Y, Baugh CM, Fritts NG, Martin BM, Chaisson C, Cantu RC, Joyce JA, Shah S, 
Ikezu T, Zhang J, Gercel-Taylor C, Taylor DD (2016) Preliminary Study of Plasma Exosomal Tau 
as a Potential Biomarker for Chronic Traumatic Encephalopathy. J Alzheimers Dis 51:1099-1109. 
Strauss K, Goebel C, Runz H, Mobius W, Weiss S, Feussner I, Simons M, Schneider A (2010) 
Exosome secretion ameliorates lysosomal storage of cholesterol in Niemann-Pick type C disease. J 
Biol Chem 285:26279-26288. 
Stuendl A, Kunadt M, Kruse N, Bartels C, Moebius W, Danzer KM, Mollenhauer B, Schneider A 
(2016) Induction of alpha-synuclein aggregate formation by CSF exosomes from patients with 
Parkinson's disease and dementia with Lewy bodies. Brain : a journal of neurology 139:481-494. 
Sun B, Dalvi P, Abadjian L, Tang N, Pulliam L (2017) Blood neuron-derived exosomes as 
biomarkers of cognitive impairment in HIV. AIDS 31:F9-F17. 
Szabo G, Momen-Heravi F (2017) Extracellular vesicles in liver disease and potential as biomarkers 
and therapeutic targets. Nature reviews Gastroenterology & hepatology 14:455-466. 
Takano T, Xu C, Funahashi Y, Namba T, Kaibuchi K (2015) Neuronal polarization. Development 
142:2088-2093. 
Thei L, Imm J, Kaisis E, Dallas ML, Kerrigan TL (2018) Microglia in Alzheimer's Disease: A Role 
for Ion Channels. Frontiers in neuroscience 12:676. 
Timbie KF, Mead BP, Price RJ (2015) Drug and gene delivery across the blood-brain barrier with 
focused ultrasound. J Control Release 219:61-75. 
Todorova D, Simoncini S, Lacroix R, Sabatier F, Dignat-George F (2017) Extracellular Vesicles in 
Angiogenesis. Circ Res 120:1658-1673. 
Tomiyama H, Lesage S, Tan EK, Jeon BS (2015) Familial Parkinson's disease/parkinsonism. 
BioMed research international 2015:736915. 
Tysnes OB, Storstein A (2017) Epidemiology of Parkinson's disease. Journal of neural transmission 
124:901-905. 
Venkatesan A, Murphy OC (2018) Viral Encephalitis. Neurologic clinics 36:705-724. 
18 
 
Vezzani A, Fujinami RS, White HS, Preux PM, Blumcke I, Sander JW, Loscher W (2016) 
Infections, inflammation and epilepsy. Acta Neuropathol 131:211-234. 
Vinuesa A, Bentivegna M, Calfa G, Filipello F, Pomilio C, Bonaventura MM, Lux-Lantos V, 
Matzkin ME, Gregosa A, Presa J, Matteoli M, Beauquis J, Saravia F (2018) Early Exposure to a 
High-Fat Diet Impacts on Hippocampal Plasticity: Implication of Microglia-Derived Exosome-like 
Extracellular Vesicles. Molecular neurobiology. 
von Bernhardi R, Eugenin-von Bernhardi J, Flores B, Eugenin Leon J (2016) Glial Cells and 
Integrity of the Nervous System. Advances in experimental medicine and biology 949:1-24. 
Wang Y, Balaji V, Kaniyappan S, Kruger L, Irsen S, Tepper K, Chandupatla R, Maetzler W, 
Schneider A, Mandelkow E, Mandelkow EM (2017) The release and trans-synaptic transmission of 
Tau via exosomes. Molecular neurodegeneration 12:5. 
Wong CH, Chen YC (2019) Clinical significance of exosomes as potential biomarkers in cancer. 
World J Clin Cases 7:171-190. 
Wright JN (2017) CNS Injuries in Abusive Head Trauma. AJR American journal of roentgenology 
208:991-1001. 
Xiao B, Chai Y, Lv S, Ye M, Wu M, Xie L, Fan Y, Zhu X, Gao Z (2017) Endothelial cell-derived 
exosomes protect SH-SY5Y nerve cells against ischemia/reperfusion injury. International journal of 
molecular medicine 40:1201-1209. 
Xu R, Greening DW, Zhu HJ, Takahashi N, Simpson RJ (2016) Extracellular vesicle isolation and 
characterization: toward clinical application. J Clin Invest 126:1152-1162. 
Yan S, Zhang H, Xie W, Meng F, Zhang K, Jiang Y, Zhang X, Zhang J (2017) Altered microRNA 
profiles in plasma exosomes from mesial temporal lobe epilepsy with hippocampal sclerosis. 
Oncotarget 8:4136-4146. 
Zhao Y, Haney MJ, Gupta R, Bohnsack JP, He Z, Kabanov AV, Batrakova EV (2014) GDNF-
transfected macrophages produce potent neuroprotective effects in Parkinson's disease mouse 
model. PLoS One 9:e106867. 
 
